Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Atopic Dermatitis: Ruxolitinib And Baricitinib Spearheading New Therapies

Wave Of New Treatments Expected Over The Next Few Years.

Executive Summary

Top-line Phase III results from Incyte’s TruE-AD2 study of ruxolitinib cream and Eli Lilly’s BREEZE-AD4 and BREEZE-AD5 studies of oral baricitinib show that the compounds achieved primary endpoints in atopic dermatitis, and they may eventually challenge Sanofi’s Dupixent’s growth in the sector.

You may also be interested in...



Lilly’s Olumiant Could Get Blood Clot Redemption With EUA For COVID

When the US FDA approved Olumiant (baricitinib) for RA, it insisted on a lower dose because of fears of blood clots. Now that an NIH trial has shown that the product plus Gilead’s Veklury (remdesivir) provided a statistically significant reduction in time to recovery versus remdesivir alone for hospitalized COVID patients, Olumaint may get an emergency use authorization from FDA to treat a condition that itself causes blood clots. That doesn't mean the black box is going away; it's just a reminder that there is as much magic and mystery to medicine sometimes as there is science. 

Lilly’s Olumiant Cuts COVID-19 Hospital Stays By One Day

Olumiant (baricitinib) plus Gilead’s Veklury (remdesivir) provided a statistically significant reduction in time to recovery versus remdesivir alone for hospitalized patients in US NIAID’s ACTT-2 clinical trial. 

AbbVie’s Rinvoq Shines In First Of Three Eczema Pivotal Studies

The JAK1 inhibitor showed skin clearance and itch reduction in first of three Phase III trials. Analysts say blockbuster atopic dermatitis indication is possible if data hold up in ongoing studies.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel